Bendamustine–rituximab elicits dual tumoricidal and ...

Basic tumor immunology. Original research. Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse ...

Bendamustine-rituximab elicits dual tumoricidal and ... - PubMed

Bendamustine-rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS-STING activation in diffuse large B-cell lymphoma. J ...

Journal for ImmunoTherapy of Cancer - X.com

New #JITC article: Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large ...

CRISP_SCIENCE on X: ""Bendamustine–rituximab elicits dual ...

"Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphoma" ...

Efficacy of bendamustine and rituximab as first salvage treatment in ...

We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL).

Nine-year updated results from the StiL NHL1 study.

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results ...

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell ...

Here, we report the primary results of the international, randomized, double-blind, phase 3 SHINE trial, in which we evaluated the combination ...

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in ...

This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab (BR) vs a standard rituximab- ...

Multicenter, Open-Label, Phase II Study of Bendamustine and ...

AbstractPurpose:. Bendamustine and rituximab (BR) has been established as a superior frontline therapy over R-CHOP in the treatment of follicular lymphoma.

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits ... - OncLive

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Abstract: LB3439 - EHA Library - European Hematology Association

ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED ECHO TRIAL.

Acalabrutinib Plus Bendamustine and Rituximab May Become New ...

Adding acalabrutinib to first-line treatment with bendamustine and rituximab can improve PFS in older patients with MCL.

Primary results from the double-blind, placebo-controlled, phase III ...

... bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL). Authors: Michael ...

Bendamustine - an overview | ScienceDirect Topics

... treatment with rituximab or a rituximab-containing regimen, and also for the treatment of patients with CLL. This new therapy for B-cell malignancies is in ...

Bendamustine + Rituximab, B-cell Lymphoma - ChemoExperts

Important side effects and package insert explained by cancer pharmacists: listen, watch videos, and learn about Bendamustine + Rituximab ...

Polatuzumab vedotin plus bendamustine and rituximab in relapsed ...

Biomarker analysis suggested that patients derived benefit from pola + BR regardless of cell-of-origin or double-expressor lymphoma status.17 Based on these ...

Idelalisib or placebo in combination with bendamustine and ...

Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia.

3792-Bendamustine polatuzumab vedotin and rituximab - eviQ

This protocol is based on limited evidence; refer to the evidence section of this protocol for more information.

Bendamustine (intravenous route) - Mayo Clinic

Bendamustine injection is used to treat chronic lymphocytic leukemia (CLL, cancer of white blood cells) and indolent B-cell non-Hodgkin's lymphoma (NHL)

ECOG-ACRIN E2408 | Clinical Cancer Research - AACR Journals

AbstractPurpose:. We sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated.